ATE314362T1 - Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung - Google Patents

Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung

Info

Publication number
ATE314362T1
ATE314362T1 AT00966408T AT00966408T ATE314362T1 AT E314362 T1 ATE314362 T1 AT E314362T1 AT 00966408 T AT00966408 T AT 00966408T AT 00966408 T AT00966408 T AT 00966408T AT E314362 T1 ATE314362 T1 AT E314362T1
Authority
AT
Austria
Prior art keywords
group
heterocycle
amino
alkyl
alkoxy
Prior art date
Application number
AT00966408T
Other languages
English (en)
Inventor
Tetsuo Miwa
Mitsuo Yamamoto
Takayuki Doi
Naoki Tarui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE314362T1 publication Critical patent/ATE314362T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00966408T 1999-10-12 2000-10-11 Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung ATE314362T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28986899 1999-10-12
PCT/JP2000/007048 WO2001027105A1 (en) 1999-10-12 2000-10-11 Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof

Publications (1)

Publication Number Publication Date
ATE314362T1 true ATE314362T1 (de) 2006-01-15

Family

ID=17748813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00966408T ATE314362T1 (de) 1999-10-12 2000-10-11 Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung

Country Status (6)

Country Link
US (1) US7087597B1 (de)
EP (1) EP1223170B1 (de)
AT (1) ATE314362T1 (de)
AU (1) AU7683500A (de)
DE (1) DE60025243T2 (de)
WO (1) WO2001027105A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552013T1 (de) * 2000-09-06 2012-04-15 Mitsubishi Tanabe Pharma Corp Zubereitungen zur oralen anwendung
DK1438053T3 (da) 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004110450A1 (en) * 2003-06-16 2004-12-23 Altana Pharma Ag Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
EP1633740B1 (de) 2003-06-19 2011-11-09 GlaxoSmithKline LLC 5-(acylamino)indazol-derivate als kinase-inhibitoren
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
NZ566722A (en) * 2005-09-15 2010-11-26 Orchid Res Lab Ltd Novel pyrimidine carboxamides
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20080051413A1 (en) * 2006-08-25 2008-02-28 Kaohsiung Medical University Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance
CA2711558C (en) 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5557832B2 (ja) * 2008-03-18 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換４−ヒドロキシピリジン−５−カルボキサミド
CA2719936A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
SG176628A1 (en) 2009-06-05 2012-01-30 Link Medicine Corp Aminopyrrolidinone derivatives and uses thereof
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
KR101255939B1 (ko) * 2011-05-31 2013-04-23 동화약품주식회사 4-(1ｈ-인다졸-6-일아미노)-ｎ-아이소프로필-2-(메틸티오)피리미딘-5-카르복스아미드 화합물 또는 이의 약학적으로 허용가능한 염을 포함하는 당뇨병 예방 또는 치료용 조성물
US8980904B2 (en) * 2011-07-21 2015-03-17 Xuanzhu Pharma Co., Ltd. Heterocyclic substituted pyrimidine compound
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9359371B2 (en) 2012-08-14 2016-06-07 Xuanzhu Pharma Co., Ltd. Bicyclic substituted pyrimidine compounds
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
EP2980087B1 (de) * 2013-03-29 2018-06-06 Xuanzhu Pharma Co., Ltd. Bicyclisches substituiertes pyrimidin-pde-5-hemmer-prodrug
AU2015217185B2 (en) * 2014-02-12 2018-04-05 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
AR101197A1 (es) * 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas
AR101198A1 (es) * 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas como inhibidores de pde4b
CN105646240A (zh) * 2014-12-02 2016-06-08 重庆安格龙翔医药科技有限公司 一种阿伐那非重要中间体的制备方法
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
CN121021491A (zh) * 2020-10-28 2025-11-28 盐野义制药株式会社 具有抗病毒活性的酰胺衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB901749A (en) 1957-12-06 1962-07-25 Ciba Ltd New 2-substituted pyrimidines
BE598759A (de) * 1960-01-04
DE2853220A1 (de) * 1978-12-09 1980-07-03 Hoechst Ag Neue amino-pyrimidin-carbanilide, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
JPS6187672A (ja) 1984-10-08 1986-05-06 Mitsui Petrochem Ind Ltd 新規ピリミジン誘導体
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
EP0799617A3 (de) 1986-02-24 1997-11-12 Mitsui Petrochemical Industries, Ltd. Therapeutisches Mittel zur Behandlung von neurologischen Krankheiten
ES2109382T3 (es) * 1992-02-22 1998-01-16 Hoechst Ag Sales solubles de n-metil-n-(3-trifluorometil-fenil)-amida del acido 4-amino-2-(4,4'-dimetil-imidazolidin-2-on-1-il)-pirimidin-5-carboxilico, procedimiento para su preparacion, su utilizacion como medicamento y productos de partida.
DE59305012D1 (de) * 1992-02-22 1997-02-20 Hoechst Ag 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
ATE163647T1 (de) * 1993-08-26 1998-03-15 Ono Pharmaceutical Co 4-aminopyrimidin derivate
DE19625088A1 (de) * 1996-06-24 1998-01-02 Hoechst Ag 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19625089A1 (de) * 1996-06-24 1998-01-02 Hoechst Ag 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19636487A1 (de) * 1996-09-09 1998-03-12 Hoechst Ag 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives

Also Published As

Publication number Publication date
WO2001027105A1 (en) 2001-04-19
AU7683500A (en) 2001-04-23
EP1223170A4 (de) 2004-03-31
US7087597B1 (en) 2006-08-08
EP1223170B1 (de) 2005-12-28
DE60025243T2 (de) 2006-06-22
EP1223170A1 (de) 2002-07-17
DE60025243D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
EP1223170A4 (de) Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
EA200970379A1 (ru) Бициклические гетероароматические соединения
EP1852434A4 (de) Bicyclisches carbamoylpyridonderivat mit hiv-integrase-hemmender wirkung
PT83310A (de) Heterocyclish substitutierte indole zwischenprodukte verfahren zu ihrer herstellung und arzneimittel
WO2005092895A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
ATE442367T1 (de) Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
DE60311821D1 (de) Dibenzylaminverbindung und deren medizinische verwendung
DE60238042D1 (de) Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11-beta-hydroxysteroid dehydrogenase
EP1259487B8 (de) 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren
HUP0401213A2 (hu) Glükokinázra ható vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
CO6150183A2 (es) Derivado heterociclico derivado con potente actividad de inhibidor de quinasa
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
MA27615A1 (fr) Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
HUT48250A (en) Process for producing new benzimidazolin-2-oxo-1-carboxylic acid derivatives of 5-ht receptor antagonistic activity and pharmaceutical compositions containing them
MY129796A (en) Novel anti-inflammatory androstane derivatives
HUP0001760A2 (hu) Aril-acil-piridazin-származékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és a vegyületek alkalmazása gyógyszerkészítmények előállítására
TW200602319A (en) Indole derivative and use thereof
CA2126465A1 (en) Inhibitor for restenosis after percutaneous coronary arterioplasty
WO2007057790A3 (en) Substituted bicyclic pyrimidone derivatives
WO2002066443A3 (en) 2-thioxo-1,2,3,4-tetrahydropyrimidine derivatives
DE69907923D1 (de) Triazolopyridazinderivate zur verbesserung der kognitiven funktionen
WO1998006400A3 (en) Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells
CA2435958A1 (en) Pyrimidine compounds and methods for making and using the same
ATE325790T1 (de) Harnstoff-verbindungen, ein verfahren zu deren herstellung und ihre verwendung
ATE106400T1 (de) Substituierte 3h-indole, verfahren zu ihrer herstellung sowie arzneimittel.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties